Core Viewpoint - The announcement indicates that the clinical trial for DB-1303/BNT323 has met its primary endpoint of progression-free survival (PFS) compared to the control group in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane treatments [1] Group 1: Clinical Trial Details - The trial is a randomized, controlled, open-label, multi-center Phase III clinical study conducted in China [1] - The objective of the trial is to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in the specified patient population [1] Group 2: Regulatory Plans - Following the interim analysis results, the company plans to communicate with the Center for Drug Evaluation of the National Medical Products Administration in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]